I
n 1999, the Institute of Medicine (IOM) sparked controversy with its report titled To Err Is Human. In this report, the IOM highlighted that health care in the United States appeared to be far behind in ensuring basic safety compared with other high-risk industries. 1, 2 The IOM report stated that errors caused between 44 000 and 98 000 deaths every year in US hospitals and over 1 million injuries. 2 In a follow-up report titled The Quality Chasm, the IOM called for an ambitious 50% reduction in medical errors.
A new national agenda for health care was subsequently put in action by government agencies that oversee the health care industry. The Agency for Healthcare Research and Quality (AHRQ), 3 part of the US Department of Health and Human Services (http://www.ahrq.gov), created a list of indicators that represent inpatient complications or adverse events that are potentially avoidable. These patient safety indicators (PSIs) are reported by many hospitals to the University Health Consortium, an alliance of 116 academic medical centers and 276 of their affiliates, to determine hospital performance. In addition to publicly available rankings based on PSIs, hospitals are incentivized to reduce inpatient complications by the Centers for Medicare and Medicaid Services (CMS) pay-for-performance program. The CMS determined a list of hospital acquired conditions (HACs) for which hospitals will not receive additional reimbursement. 3 The impact of these measures to ensure patient safety and quality is still unknown and continues to generate controversy. Measuring the success or failure of these programs will require surveys of large patient populations, such as the data available through the Nationwide Inpatient Sample database (NIS). These metrics are especially relevant to brain tumor patients who are at high risk for morbidity and mortality due to their underlying diagnoses. These metrics are now being used to determine the safety and quality of care being delivered by health care systems and providers and will be linked directly to reimbursement. Therefore, it is important to determine the national rates for these metrics in brain tumor patients to better understand the benchmarks specifically for this patient population. It is also important to know what factors influence the likelihood of a brain tumor patient developing a PSI or HAC during hospitalization. To better understand these metrics in hospitalized brain tumor patients, we determined the incidence rates of PSIs and HACs among patients with a diagnosis of a brain tumor in the NIS.
Materials and Methods
We queried the NIS, part of the AHRQ's Healthcare Cost and Utilization Project, for all hospitalizations between 2002 and 2010 involving a brain tumor. These data included all hospitalizations with codes from the International Classification of Diseases, 9th Revision (ICD-9) for a brain tumor (eg, 191.0-0.9, 225.0-0. 2, 225.9, 198.3, 192 .1, 239.6, 237.1, 237.5-0.6, 227.3-0.4). To identify patients who had undergone surgery, we used brain tumor surgery ICD-9 codes (011.3, 011.4, 040.1, 015.1, 015.3, 015.9). The incidence rate of a particular PSI or HAC among these hospitalizations was determined by summing the number of hospital records that included the ICD-9 code or codes indicating the presence of each PSI or HAC (Table 1) . The NIS is the largest all-payer hospital inpatient database and contains data approximating a 20% stratified sample of US hospitals.
Statistical Methods
We used the SAS v9.3 statistical software package to calculate means, standard deviations, and frequencies for all patient and hospital characteristics and to estimate all PSI and HAC incidence rates. The NIS is a sample of US hospitals stratified by region, location/teaching status, bedsize category, and ownership. We followed methods outlined in NIS documentation (http://www.hcup-us. ahrq.gov) to account for this stratification in our estimates of the total number of brain tumor hospitalizations for the years 2002 -2010 and the national incidence and incidence rates of each indicator during that period among these patients.
We performed multivariable analysis of all indicators that had an observed incidence rate of .0.1%. An overall comorbidity score was generated for use as a covariate by summing the number of Elixhauser comorbidities 4 recorded in the NIS for each hospitalization. We used generalized estimating equations (SAS PROC GENMOD, v9.3) to assess possible associations between patient and hospital characteristics and AHRQ and CMS indicators. In all models, the presence of the indicator (yes or no) was taken as the outcome variable. The patient's age, gender, and comorbidity score and the hospital type (teaching vs nonteaching), region (Northeast, Midwest, South, or West), and bedsize (small, medium, or large) were included as covariates. Results for hospital region were largely uninformative, showing no clear patterns, and were omitted. For all models, we graphically assessed the relationship between the probability of having the indicator and age, comorbidity score, and hospital bedsize. We used these results and the quasi-likelihood information fit criterion for generalized estimating equation models to determine whether any particular covariate modification (typically, adding a quadratic term in age or treating bedsize as an ordered rather than a nominal variable) resulted in a better fit than the baseline model. We assumed a binary distribution for the outcome variable, with a logit link function. To account for the clustering of observations on hospitals, we treated hospital as a repeated factor and assumed an exchangeable working correlation. Table 3 ).
Results
The total number of HACs associated with brain tumor patients was 13 778, with 13 187 patients (2.63%) experiencing ≥1 HACs. The most common HACs were falls and trauma (ENR for any type of fall/ trauma ¼ 2.09%, 95% CI ¼ 2.05%, 2.13%) and stage III-IV pressure ulcers from 2008 to 2010 (ENR ¼ 0.384%, 95% CI ¼ 0.357%, 0.414%) ( Table 4) .
Patients Treated Without Surgery
Of the 501 908 brain tumor patients found in the NIS, 421 672 (84%) were treated without surgery. The total number of PSIs in brain tumor patients treated without surgery was 92 275, with a total of 72 485 patients (17.2%) experiencing ≥1 PSI. The number of HACs in brain tumor patients treated without surgery was 13 161, with 12 596 (3.0%) experiencing ≥1 HAC.
Patients Treated With Surgery
Of the 501 908 brain tumor patients found in the NIS, 80 236 (16%) were treated with surgery. The number of PSIs in brain tumor patients treated with surgery was 9771, with 7859 patients (9.79%) experiencing ≥1 PSI. HACs in brain tumor patients treated with surgery occurred 617 times, with 591 (7.4%) experiencing ≥1 HAC.
Length of Stay
For PSIs, almost all of the indicators resulted in increased length of stay (LOS), except for anesthetic complications, postoperative physiologic derangement, postoperative wound dehiscence, and transfusion reaction ( Table 3) . Most of the increases of LOS were only by a couple of days. However, pressure ulcer, foreign body, central venous line (CVL) infection, postoperative hemorrhage and respiratory failure, and sepsis were associated with twice as long LOS. HACs associated with increased LOS included retained foreign object, air embolism, pressure ulcers, falls and trauma, catheter-associated urinary tract infection (UTI), vascular catheter-associated infection, manifestation of poor glycemic control, surgical site infections following orthopedic procedures, and DVT (Table 4) . Almost all of these were associated with a doubling of LOS except for surgical site infection following certain orthopedic procedures, which was associated with an impressive 5× increase in LOS.
Effect of Age and Gender on Incidence of PSIs and HACs
For PSIs, increasing age in brain tumor patients was associated with a linearly increasing risk of having a pressure ulcer (odds ratio [OR] × 1.015 for each additional year of age, P , .0001), iatrogenic pneumothorax (OR × 1.010 for each additional year of age, P , .0001), and postoperative hip fracture (OR × 1.06 for each additional year of age, P , .0001) (Supplementary Table S1 ). PSIs that linearly decreased with aging included CVL infection (OR × 0.957 for each additional year of age, P , .0001), postoperative physiologic derangement (OR × 0.982 for each additional year of age, P , .0001), and sepsis (OR × 0.994 for each additional year of age, P , .0001). The risk of postoperative respiratory failure was estimated to decrease exponentially with age (P , .0001) in brain tumor patients. DVT risk increased exponentially until the age of 58 and then decreased exponentially with age (P , .0001). Similarly, PE risk increased exponentially until the age of 56 and then decreased exponentially with age (P , .0001).
For HACs, increasing age in brain tumor patients was associated with linearly increased risk of stage III-IV pressure ulcers (OR × 1.010 for each additional year of age, P , .01) and catheter-associated UTI (OR × 1.020 for each additional year of age, P ¼ .0014) (Supplementary Table S2 ). Vascular catheter-associated infection risk decreased linearly with increasing age (OR × 0.953, P , .0001), as did manifestations of poor glycemic control (OR × 0.984, P , .0001). Falls and trauma risk increased exponentially with age (P , .0001).
For PSIs, male gender was associated with increased likelihood of iatrogenic pneumothorax (OR ¼ 1.12, P , .01), postoperative respiratory failure (OR ¼ 1.24, P , .0001), DVT (OR ¼ 1.13, P , .0001), PE (OR ¼ 1.20, P , .0001), and sepsis (OR ¼ 1.17, P , .0001) (Supplementary Table S3 ). Male gender was associated with a decreased likelihood of CVL infection (OR ¼ 0.85, P , .0001), postoperative hip fracture (OR ¼ 0.52, P , .0001), postoperative physiologic 
Effect of Comorbidity Score on PSIs and HACs
Increasing comorbidity score was estimated to increase risk of all PSIs and HACs studied in multivariable analysis (those with incidence rates .0.1%). For PSIs, the increase in risk was linear for pressure ulcer (OR × 1.43 for each additional comorbidity, P , .0001), iatrogenic pneumothorax (OR × 1.07, P , .0001), postoperative hip fracture (OR × 1.25, P , .0001), postoperative hemorrhage (OR × 1.12, P , .0001), postoperative respiratory failure (OR × 1.39, P , .0001), DVT (OR × 1.24, P , .0001), and PE (OR × 1.36, P , .0001) ( Table 5 , Figures 1-6 ). Increasing comorbidity score was associated with exponential increases in CVL infection, postoperative physiologic derangement, and sepsis (P , .0001 for all). For HACs, increasing comorbidity score was associated with linearly increased risk of manifestations of poor glycemic control (OR × 1.51, P , .0001) and catheterassociated UTI (OR × 1.19, P , .001). The risks of pressure ulcers, falls and trauma, and vascular catheterassociated infections were estimated to increase exponentially with increasing comorbidity score (P , .0001).
Hospital Type and Size Effect on PSIs and HACs
The likelihood of being diagnosed with a PSI or HAC was higher for patients admitted to nonteaching hospitals for postoperative hip fractures (OR ¼ 1.38, P , .0001), postoperative physiologic derangement (OR ¼ 1.17, P ¼ .03), sepsis (OR ¼ 1.19, P , .0001), falls and trauma (OR ¼ 1.10, P , .001), and manifestations of poor Central venous line infection Risk is estimated to increase quickly for low CM scores but more slowly for higher scores (P . .0001) (Fig 1) .
Postoperative hip fracture X ¼ 1.25, CI ¼ [1.22, 1.28], P , .0001
Postop physiologic derangement, any Risk is estimated to increase quickly for low CM scores, but more slowly for higher scores (P . .0001) (Fig 2) . Sepsis Risk is estimated to increase quickly for low CM scores, but more slowly for higher scores (P . .0001) (Fig 3) . Accidental puncture or laceration P . .05
Hospital acquired conditions
Pressure ulcer stages III-IV Risk is estimated to increase quickly for low CM scores, but more slowly for higher scores (P . .0001) (Fig 4) .
Falls and trauma, any
Risk is estimated to increase quickly for low CM scores, but more slowly for higher scores (P . .0001) (Fig 5) .
Vascular catheter-associated infection
Risk is estimated to increase quickly for low CM scores, but more slowly for higher scores (P . .0001) (Fig 6) . Table S4 ). The risks of pressure ulcer, postoperative hemorrhage, postoperative respiratory failure, DVT, and accidental puncture were estimated to increase with hospital bedsize (Supplementary Table S5 ).
Discussion
PSIs and HACs are extremely common in brain tumor patients, especially those treated without surgery. The relatively low rates of PSIs and HACs in surgically treated brain tumor patients reflects the ability of surgeons to appropriately choose low-risk patients for surgical treatment. Surgical patients were more likely to be treated at teaching institutions. Not surprisingly, postoperative respiratory failure, DVT, and sepsis were among the most common PSIs/HACs identified. As expected, increasing comorbidities were associated with increased incidence of almost all PSIs and HACs. Overall, the rates of PSIs and HACs in the NIS were comparable to rates from other databases. 5 Metrics like PSIs and HACs are sets of administrative data-based indicators used to identify in-hospital patient safety events. 6 Movements to track these metrics have their roots in the IOM's definition of patient safety: "freedom from accidental injury caused by medical care." 2 This definition has been expanded to include "the failure of a planned action to be completed as intended or the use of a wrong plan to achieve an aim. Errors can include problems in practice, products, procedures, and systems." 7 Due to implications of the incidence of PSIs/HACs for hospitals and physicians regarding reimbursement and ratings, significant effort is now being invested in accurately coding patient preadmission risk profiles and preventing inpatient harm events. Standardized procedural protocols have been highly successful in reducing the number of patient harm events. 8 -10 Despite changes in identification of higher-risk patients and standardization of treatment, PSIs and HACs continue to be reported in high numbers. 11, 12 In response to this reality, the Partnership for Patients was launched in 2011 by the US Secretary of Health and Human Services. The Partnership for Patients is an effort designed to reduce patient harm events by 40% in 2013 compared with 2010 and to reduce preventable hospital readmissions within 30 days by 20% in 2013 compared with 2010. 12 The effects of these types of initiatives on a national scale will take years to determine. In the meantime, individual institutions will be able to use databases such as that of the University Health Consortium and the NIS for relative comparisons of PSI and HAC rates.
Study Limitations
Limitations of this study include its retrospective nature and potential for selection bias. The NIS also has the potential for coding errors and variability in coding.
Our data are limited because the NIS does not allow distinction between preadmission conditions and hospital acquired diagnoses. Therefore, some of these reported PSIs and HACs may have been present on admission. This may be much more likely for certain conditions (eg, physiologic and metabolic derangements, sepsis, DVT) compared with others (eg, anesthetic complication, transfusion reaction).
Brain tumor patients are at high risk for experiencing a PSI or HAC. This reality seems to be recognized by neurosurgeons, explaining the association of nonsurgical treatment of brain tumors and elevated rates of PSIs and HACs. These data are important when counseling patients about the diagnosis and treatment of brain tumors. Importantly, these values provide baselines for hospital comparisons and quality standards.
Conclusion
Patient safety and delivery of quality care is an important part of our national health care agenda. Systems are being put in place to monitor and ensure patient safety. Our results demonstrate baseline national rates of PSIs and HACs in brain tumor patients. These data may be used to determine individual institutional improvements or success by comparison. Further prospective studies are required to accurately determine the true incidence of these patient safety metrics in a neurosurgical population.
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